安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- NEJM Author Center - The New England Journal of Medicine
The New England Journal of Medicine (NEJM) continues to lead in the publication of influential, highly cited clinical research
- Continuing Medical Education - The New England Journal of Medicine
This review summarizes the genetics, diagnosis, and treatment of long QT syndrome, a major cause of sudden death in young people Risk stratification and genotype-guided therapy are essential
- Encorafenib, Cetuximab, and mFOLFOX6 in - The New England Journal of . . .
First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer
- Zongertinib in Previously Treated - The New England Journal of Medicine
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC) Zongertinib is an oral
- First-Line Camizestrant for Emerging - The New England Journal of Medicine
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
- Remibrutinib in Chronic Spontaneous Urticaria | New England Journal of . . .
Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks Remibrutinib, an oral, highly sel
- Overall Survival with Inavolisib in - The New England Journal of Medicine
In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo
|
|
|